Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
Bijay S. Jaiswal(AbbVie (United States)), Somasekar Seshagiri(Sarepta Therapeutics (United States))
Cited by 108
Related Papers
Recurrent R-spondin fusions in colon cancer
|Nature|2012|973
Spectrum of diverse genomic alterations define non–clear cell renal carcinoma subtypes
|Nature Genetics|2014|359
Conditional activation of Pik3caH1047R in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations
|Oncogene|2012|73
Regulation of ERK3/MAPK6 expression by BRAF
|International Journal of Oncology|2006|32